Comparative evaluation shows Imatinib and Nilotinib enhance neuroprotection and reduce inflammation in Alzheimer’s, suggesting potential for human research.
Imatinib and Nilotinib ameliorated neuroinflammation, restored neurotrophic support, and improved cognitive deficits in a preclinical Alzheimer's disease model. These findings highlight the therapeutic potential of tyrosine kinase inhibitors, warranting further translational research in human studies.
No takes yet. Share an insight, caveat, or question.
Gürkan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: